CelLBxHealth plc Stock
Stocks
CLBX
GB0034330679
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.275 GBX | 0.00% |
|
0.00% | +15.91% |
| 07-15 | Beeks in "strong" year; Iofina output up | AN |
| 07-15 | CelLBxHealth plc Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 14.49M 19.25M 16.91M 15.79M 27.12M 1.84B 27.79M 187M 73.21M 912M 72.27M 70.7M 3.15B | P/E 2026 * |
-0.55x | P/E 2027 * | -14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 12.89M 17.12M 15.05M 14.04M 24.13M 1.64B 24.72M 167M 65.13M 812M 64.29M 62.89M 2.81B | EV / Sales 2026 * |
0.6x | EV / Sales 2027 * | 0.42x |
| Free-Float |
94.31% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: CelLBxHealth plc
| 25-10-16 | Angle names Peter Collins as interim CEO | AN |
| 25-05-28 | RBC cuts National Grid; Citigroup cuts South32 | AN |
| 25-01-23 | HSBC raises FirstGroup, Goldman cuts Ithaca | AN |
| 23-09-14 | JPMorgan ups Rio Tinto; Redburn likes Carnival | AN |
| 22-01-24 | Berenberg Initiates Angle With Buy Rating, Sets PT | MT |
| Current month | -16.39% | ||
| 1 month | -16.39% | ||
| 3 months | +37.84% | ||
| 6 months | +6.25% | ||
| Current year | +15.91% |
| 1 week | 1.2 |  | 1.35 |
| 1 month | 1.2 | | 1.67 |
| Current year | 0.85 | | 2.8 |
| 1 year | 0.85 | | 8 |
| 3 years | 0.85 | | 37.4 |
| 5 years | 0.85 | | 163.75 |
| 10 years | 0.85 | | 163.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sinéad Armstrong
DFI | Director of Finance/CFO | - | 1998-12-31 |
| Chief Tech/Sci/R&D Officer | - | 2024-12-31 | |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 2023-06-04 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Groen
CHM | Chairman | 67 | 2023-05-21 |
Klaas de Boer
BRD | Director/Board Member | 61 | 2026-01-11 |
| Director/Board Member | 61 | 2026-01-11 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 12/19/25 | Buy | Chief Financial Officer | 2,500,000 | 0.7749% | ||
| 12/19/25 | Buy | Chairman | 5,000,000 | 1.5497% | ||
| 12/19/25 | Buy | Chief Executive Officer | 5,000,000 | 1.5497% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | -78.75% | -91.64% | 19.28M | |
| +1.44% | +1.94% | +15.78% | -38.48% | 15.69B | |
| +0.63% | +10.05% | +0.58% | +99.42% | 1.74B | |
| -1.02% | -1.08% | -35.14% | -81.06% | 1.14B | |
| +0.88% | -2.40% | -38.94% | +14.13% | 976M | |
| +2.34% | +2.73% | -44.06% | -53.05% | 633M | |
| +1.73% | +1.89% | -46.79% | -56.39% | 517M | |
| -1.62% | +2.72% | +40.20% | -52.49% | 470M | |
| +2.26% | +3.59% | -55.27% | -60.00% | 376M | |
| +5.68% | +5.39% | -15.50% | -31.11% | 355M | |
| Average | +1.23% | +1.69% | -25.79% | -35.07% | 2.19B | |
| Weighted average by Cap. | +1.27% | +1.54% | +5.00% | -28.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 21.65M 28.76M 25.27M 23.59M 40.53M 2.75B 41.53M 280M 109M 1.36B 108M 106M 4.71B | 37.75M 50.15M 44.07M 41.13M 70.67M 4.8B 72.41M 488M 191M 2.38B 188M 184M 8.22B |
| Net income | -8.55M -11.36M -9.98M -9.32M -16.01M -1.09B -16.4M -110M -43.2M -538M -42.65M -41.72M -1.86B | -1.85M -2.46M -2.16M -2.02M -3.46M -235M -3.55M -23.9M -9.35M -116M -9.23M -9.03M -403M |
| Net Debt | -1.6M -2.13M -1.87M -1.74M -3M -204M -3.07M -20.67M -8.08M -101M -7.98M -7.81M -348M | 1.4M 1.86M 1.63M 1.53M 2.62M 178M 2.69M 18.09M 7.07M 88.15M 6.98M 6.83M 305M |
Employees
114
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-29 | GBX 1.275 | 0.00% | 1,564,728 |
| 26-07-28 | GBX 1.275 | 0.00% | 343,576 |
| 26-07-27 | GBX 1.275 | 0.00% | 933,097 |
| 26-07-24 | GBX 1.275 | 0.00% | 1,482,927 |
| 26-07-23 | GBX 1.275 | 0.00% | 563,815 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0128GBP
Average target price
0.0400GBP
Spread / Average Target
+213.73%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- CLBX Stock
Select your edition
All financial news and data tailored to specific country editions
